ArticlePharmacy world & science : PWS2010
Cardiovascular risk screening program in Australian community pharmacies.
Article in Pharmacy world & science : PWS, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Pharmacists' involvement in physical activity promotion in community pharmacy: a systematic review.European journal of public health · 2024Pooled it
- Pooled it
- Osteoporosis screening in Australian community pharmacies: A mixed methods study.Health promotion journal of Australia : official journal of Australian Association of Health Promotion Professionals · 2025Article
- Patient uptake and outcomes following pharmacist-initiated referrals to general practitioners for asthma review.NPJ primary care respiratory medicine · 2022Article
- Physicians' views on cardiovascular disease risk prevention services by pharmacists and potential for collaboration.Exploratory research in clinical and social pharmacy · 2021Article
- Identifying the Knowledge Structure and Trends of Outreach in Public Health Care: A Text Network Analysis and Topic Modeling.International journal of environmental research and public health · 2021Article
- Cardiovascular disease risk prevention services by pharmacists in Saudi Arabia: what do policymakers and opinion leaders think?Journal of pharmaceutical policy and practice · 2021Article
- Pharmacists' roles in supporting people living with severe and persistent mental illness: a systematic review protocol.BMJ open · 2020Article
- Awareness campaigns of atrial fibrillation as an opportunity for early detection by pharmacists: an international cross-sectional study.Journal of thrombosis and thrombolysis · 2020Article
- Australian Community Pharmacists' Experience of Implementing a Chronic Kidney Disease Risk Assessment Service.Preventing chronic disease · 2018Article
- Patient satisfaction with a chronic kidney disease risk assessment service in community pharmacies.International journal of clinical pharmacy · 2018Article
- Community pharmacy COPD services: what do researchers and policy makers need to know?Integrated pharmacy research & practice · 2017Review
- A web-based training program to support chronic kidney disease screening by community pharmacists.International journal of clinical pharmacy · 2016Article
- Atrial fibrillation screening in pharmacies using an iPhone ECG: a qualitative review of implementation.International journal of clinical pharmacy · 2015Article
- The effectiveness of screening for diabetes and cardiovascular disease risk factors in a community pharmacy setting.PloS one · 2014Article
- Pharmacy staff opinions regarding diabetic retinopathy screenings in the community setting: findings from a brief survey.American health & drug benefits · 2013Article
- The role of community pharmacists in screening and subsequent management of chronic respiratory diseases: a systematic review.Pharmacy practice · 2013Article
- The MyHealthCheckup study: Training graduate students to implement cardiovascular risk screening programs in community pharmacies.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC · 2012Article
- Community pharmacists' perceptions of services that benefit older people in New Zealand.International journal of clinical pharmacy · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the suitability of Australian community pharmacies as cardiovascular disease risk profile screening centres and evaluate whether community pharmacists can play an important role in detecting, educating and referring screened individuals at high risk of cardiovascular disease.
setting14 Australian community pharmacies.
methodOpportunistic cardiovascular disease risk profiling for members of the public aged greater than 30 years with no existing cardiovascular diseases was performed. All major cardiovascular risk factors were measured. Exercise habits, existing conditions and therapy, and family history were also assessed. The results were used to calculate each subject's 10-year risk of developing cardiovascular events, based on Framingham Risk Equations (New Zealand tables). Each subject's knowledge of cardiovascular risk factors was assessed using a multiple-choice questionnaire. Written educational materials and verbal counselling were provided. Referral to a doctor for further assessment was recommended as appropriate. The screened individuals were followed up via mailed out questionnaire. A random sample of individuals at elevated risk was phoned to assess for outcomes of the screening and referral process.
main outcome measuresRisk of developing cardiovascular disease and knowledge of cardiovascular risk factors.
resultsA total of 655 individuals (71.4% female) were screened for cardiovascular disease risk factors. Ages ranged from 30 to 90 years (median: 54 years) and 14.2% were smokers. Of the individuals screened, 28.1% had a 10-year risk of developing cardiovascular disease greater than 15%, including 6.9% who had a 10-year risk above 30%. The median calculated 10-year risk of developing cardiovascular disease was 9.5%. Approximately one-third of the individuals had elevated blood pressure, and almost two-thirds were either overweight or obese. The mean total serum cholesterol was 5.31 mmol/l, with 40% of individuals having a level above 5.5 mmol/l and 20% having a high-density lipoprotein cholesterol level below 1.0 mmol/l. There was a statistically significant improvement in the knowledge of cardiovascular disease risk factors at follow-up. Almost half of the contacted high-risk subjects reported lifestyle changes or started drug therapy following re-testing by their general practitioner.
conclusionA pharmacy-based cardiovascular disease risk profile screening and education program has the potential to identify and refer many undiagnosed individuals at high risk of cardiovascular events, and help contain the burden of heart disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.